
VolitionRx Limited VNRX
$ 2.51
6.6%
Quarterly report 2026-Q1
added 05-14-2026
VolitionRx Limited Total Assets 2011-2026 | VNRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.9 M | 9.4 M | 28 M | 18.3 M | 27.5 M | - | 21.3 M | 17.5 M | 14.6 M | 24.7 M | 7.71 M | 3.43 M | 2.07 M | 2.22 M | - | 1.22 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28 M | 1.22 M | 13.2 M |
Quarterly Total Assets VolitionRx Limited
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.04 M | 6.45 M | 8.7 M | 8.52 M | 9.4 M | 12.7 M | 13.1 M | 19.4 M | 28 M | 18 M | 27.6 M | 18 M | 18.3 M | 23.3 M | 24.3 M | 31.7 M | 27.5 M | 30 M | 35.2 M | 40.5 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 7.71 M | 7.71 M | 7.71 M | 7.71 M | 3.43 M | 3.43 M | 3.43 M | 3.43 M | 2.07 M | 2.07 M | 2.07 M | 2.07 M | 2.22 M | 2.22 M | 2.22 M | 2.22 M | 2.25 M | 2.25 M | 2.25 M | 2.25 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.5 M | 2.07 M | 15 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Castle Biosciences
CSTL
|
579 M | $ 19.72 | 2.71 % | $ 572 M | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.36 | 2.57 % | $ 495 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 114.94 | 1.22 % | $ 9.48 B | ||
|
Agilent Technologies
A
|
10.7 B | $ 113.33 | 2.5 % | $ 34.5 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.8 | - | $ 7.96 M | ||
|
Celcuity
CELC
|
467 M | $ 138.86 | 6.03 % | $ 6.49 B | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 2.31 | 17.26 % | $ 3.07 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Illumina
ILMN
|
6.3 B | $ 141.35 | -0.24 % | $ 22.5 B | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
2.01 B | $ 113.24 | 15.33 % | $ 14.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 21.1 | 2.78 % | $ 1.12 B | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 96.33 | 3.7 % | $ 6.5 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 421.05 | 0.27 % | $ 12.1 B | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 082.63 | 3.03 % | $ 22.3 B | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
National Research Corporation
NRC
|
135 M | $ 19.2 | 2.4 % | $ 430 M | ||
|
Natera
NTRA
|
1.39 B | $ 202.96 | 3.53 % | $ 20 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 156.38 | 2.59 % | $ 7.75 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Personalis
PSNL
|
334 M | $ 7.86 | 11.58 % | $ 701 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.79 | 4.77 % | $ 1.13 B | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 3.74 | 5.21 % | $ 346 M | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 26.76 | 2.71 % | $ 25.4 B | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 449.72 | 0.43 % | $ 170 B | ||
|
Senseonics Holdings
SENS
|
126 M | $ 5.69 | 2.62 % | $ 237 M | ||
|
Twist Bioscience Corporation
TWST
|
642 M | $ 54.25 | 9.6 % | $ 3.24 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
564 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.35 | -1.26 % | $ 5.4 M | ||
|
Trinity Biotech plc
TRIB
|
103 M | $ 0.6 | 6.65 % | $ 216 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 257.11 | 1.35 % | $ 21.4 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
5.08 B | $ 341.81 | 2.57 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 8.73 | 4.49 % | $ 1.89 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 193.73 | 1.75 % | $ 21.5 B |